Staff editor
Arthur Ouwehand, Technical Fellow at IFF Finland, discusses the components and vulnerabilities of the gut barrier and reviews how probiotics and related dietary interventions can support its structure and function.
MaaT Pharma, based in Lyon and listed on Euronext Paris, unveiled the final results of its ARES Phase 3 trial of Xervyteg® (MaaT013).
Akari Hiraku, researcher at Innovative Research Institute, Morinaga Milk Industry Co., presented clinical data on Bifidobacterium longum subsp. infantis M-63, a probiotic strain with a remarkable capacity to utilize HMOs.
2 December event in Brussels will unveil new socio-economic analysis on how clearer EU rules for probiotics could cut healthcare costs, drive innovation and strengthen the single market.
Pediatrics, Industry
Sponsored by
Bifidobacterium breve 2TA, Lacticaseibacillus rhamnosus L13B, and Lactobacillus gasseri L6 are not just bacteria: they are witnesses to the intimate, ancestral dialogue between mothers, infants, and microbes.
Philippe Langella, Research director at INRAE, talks about how F. prausnitzii could be a beneficial commensal.
Yvan Vandenplas, Head of the Pediatric Hospital at the University Hospital Brussels, uses the example of probiotics in acute gastroenteritis to highlight how heterogeneous methodologies in evidence synthesis can lead…
CORAL can sample the microbes residing in upper gut in a non-invasive and reliable way, offering a tool for studying the diversity of the microbiota.
Industry
Sponsored by
Through this collaboration, the Icelandic tradition of dairy innovation merges with Italian scientific expertise to drive the future of functional nutrition.
At the 67th ASH, one of hematology’s biggest stages, the Lyon-based biotech will present pivotal Phase 3 results that can bend treatment paradigms.
